Related Experiment Videos
Sinus node dysfunction in 128 patients. A retrospective study with follow-up
Insights
Sinus node dysfunction (SND) presents a varied clinical spectrum with a generally good prognosis. However, brady-tachy syndrome patients face risks of systemic embolism, suggesting a need for anticoagulant therapy.
Area of Science:
- Cardiology
- Electrophysiology
Background:
- Sinus node dysfunction (SND) is a complex cardiac condition affecting heart rhythm.
- Understanding the clinical spectrum and prognosis of SND is crucial for patient management.
Purpose of the Study:
- To analyze the clinical characteristics, progression, and outcomes of patients with sinus node dysfunction.
- To evaluate the effectiveness of different treatment modalities and identify risk factors for adverse events.
Main Methods:
- Retrospective study of 128 patients with SND over a 6-year period.
- Classification of patients into three groups based on ECG criteria: sinus bradycardia, sinoatrial block/sinus arrest, and brady-tachy syndrome.
- Follow-up of 104 patients for approximately three years to assess outcomes, including mortality and embolic events.
Main Results:
- Symptom severity increased across the ECG groups.
- Pacemaker treatment was required in 40% of patients; medical treatment was successful in 17%.
- Systemic embolic events were predominantly observed in patients with brady-tachy syndrome, with nine cases identified.
Conclusions:
- SND has a broad clinical spectrum and a generally favorable prognosis, often with a slow or stationary course.
- Brady-tachy syndrome is associated with a significant risk of systemic embolism, potentially leading to death or disability.
- Long-term anticoagulant therapy is recommended for patients with brady-tachy syndrome to mitigate embolic risks.
Abstract:
A retrospective study covering all admissions during a 6-year period revealed 128 patients with sinus node dysfunction (SND). The patients were grouped according to the ECG criteria chosen: group I 33 patients with sinus bradycardia, group II 37 with sinoatrial block/sinus arrest, group III 58 with brady-tachy syndrome. Additional heart disease, predominantly ischaemic, was found in 56%. The frequency and severity of symptoms increased from group I to group III. Pacemaker treatment was given to 40% of the cases, while medical treatment alone was successful in 17%. A follow-up including 104 patients was carried out after a mean observation period of approximately three years. Sixteen patients had died. The cause of death may have been SND per se in only one case. Five patients died of apoplectic insults or complications to such. In total, nine possible or proven systemic embolic events were found--all occurring in patients with brady-tachy syndrome. A progression of the ECG abnormality from a lower to a higher group took place in nine patients during the observation period. It is concluded that SND is a condition with a broad clinical spectrum and a stationary or slowly progressive course. In general, it carries a good prognosis. A substantial number of deaths of disabilities in patients with brady-tachy syndrome may be ascribed to systemic embolism. Long-term anticoagulant therapy is proposed in this subgroup of patients with SND.